vs

Side-by-side financial comparison of AC Immune SA (ACIU) and Qudian Inc. (HTT). Click either name above to swap in a different company.

AC Immune SA is the larger business by last-quarter revenue ($1.4M vs $1.1M, roughly 1.3× Qudian Inc.). Qudian Inc. runs the higher net margin — 239.8% vs -1622.4%, a 1862.2% gap on every dollar of revenue.

AC Immune SA is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics and diagnostic solutions for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and rare tauopathies. It operates globally, partners with leading pharmaceutical enterprises, and prioritizes addressing unmet medical needs in neurological care segments.

Qudian Inc. is a China-based fintech service provider that mainly offers small consumer credit solutions, risk management technical services, and related digital financial products. Its core target users are young mass consumers across China, with all key business operations focused on the domestic Chinese market.

ACIU vs HTT — Head-to-Head

Bigger by revenue
ACIU
ACIU
1.3× larger
ACIU
$1.4M
$1.1M
HTT
Higher net margin
HTT
HTT
1862.2% more per $
HTT
239.8%
-1622.4%
ACIU

Income Statement — Q2 FY2025 vs Q3 FY2024

Metric
ACIU
ACIU
HTT
HTT
Revenue
$1.4M
$1.1M
Net Profit
$-23.3M
$2.6M
Gross Margin
11.1%
Operating Margin
-1484.5%
-121.7%
Net Margin
-1622.4%
239.8%
Revenue YoY
90.1%
Net Profit YoY
6.9%
EPS (diluted)
$0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACIU
ACIU
HTT
HTT
Q2 25
$1.4M
Q3 24
$1.1M
Q2 24
$755.7K
$1.0M
Q1 24
$1.1M
Q3 23
$559.9K
Q3 22
$4.3M
$2.1M
Q2 22
$2.2M
Q1 22
$4.4M
Net Profit
ACIU
ACIU
HTT
HTT
Q2 25
$-23.3M
Q3 24
$2.6M
Q2 24
$-25.0M
$1.9M
Q1 24
$-1.4M
Q3 23
$-3.4M
Q3 22
$-14.9M
$-12.6M
Q2 22
$-1.3M
Q1 22
$-3.1M
Gross Margin
ACIU
ACIU
HTT
HTT
Q2 25
Q3 24
11.1%
Q2 24
13.3%
Q1 24
Q3 23
Q3 22
Q2 22
61.0%
Q1 22
84.1%
Operating Margin
ACIU
ACIU
HTT
HTT
Q2 25
-1484.5%
Q3 24
-121.7%
Q2 24
-3051.1%
-107.6%
Q1 24
-129.9%
Q3 23
-340.6%
Q3 22
-342.2%
-272.1%
Q2 22
-27.8%
Q1 22
-32.9%
Net Margin
ACIU
ACIU
HTT
HTT
Q2 25
-1622.4%
Q3 24
239.8%
Q2 24
-3313.0%
187.1%
Q1 24
-131.8%
Q3 23
-612.3%
Q3 22
-343.6%
-588.2%
Q2 22
-58.1%
Q1 22
-70.8%
EPS (diluted)
ACIU
ACIU
HTT
HTT
Q2 25
Q3 24
$0.01
Q2 24
$0.01
Q1 24
$-0.01
Q3 23
$-0.02
Q3 22
$-0.05
Q2 22
$-0.01
Q1 22
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACIU
ACIU
HTT
HTT
Cash + ST InvestmentsLiquidity on hand
$28.3M
$104.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$82.2M
$225.2M
Total Assets
$209.2M
$246.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACIU
ACIU
HTT
HTT
Q2 25
$28.3M
Q3 24
$104.9M
Q2 24
$56.7M
$112.8M
Q1 24
$140.6M
Q3 23
$183.4M
Q3 22
$49.0M
$154.1M
Q2 22
$168.3M
Q1 22
$180.3M
Total Debt
ACIU
ACIU
HTT
HTT
Q2 25
Q3 24
Q2 24
Q1 24
Q3 23
Q3 22
Q2 22
$521.5K
Q1 22
Stockholders' Equity
ACIU
ACIU
HTT
HTT
Q2 25
$82.2M
Q3 24
$225.2M
Q2 24
$135.8M
$217.5M
Q1 24
$218.9M
Q3 23
$226.0M
Q3 22
$209.1M
$225.5M
Q2 22
$253.0M
Q1 22
$269.4M
Total Assets
ACIU
ACIU
HTT
HTT
Q2 25
$209.2M
Q3 24
$246.8M
Q2 24
$261.3M
$227.9M
Q1 24
$234.9M
Q3 23
$239.4M
Q3 22
$226.1M
$249.6M
Q2 22
$283.4M
Q1 22
$296.3M
Debt / Equity
ACIU
ACIU
HTT
HTT
Q2 25
Q3 24
Q2 24
Q1 24
Q3 23
Q3 22
Q2 22
0.00×
Q1 22

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons